Metabolic & Endocrine
Diabetic Ketoacidosis
17
Pipeline Programs↗
5
Active Trials↗
7
Companies Involved↗
Diabetic Ketoacidosis is an emerging landscape with 17 programs across 7 companies. The most active players are Sanofi, Eli Lilly, POLYSAN Scientific & Technological Pharmaceutical Company. 2 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 1
No programs
Phase 24
Phase 32
Analysis
Trial Status
20
clinical trials
Completed10 · 50%
Terminated4 · 20%
Recruiting3 · 15%
Not yet recruiting2 · 10%
Unknown status1 · 5%
Clinical Trials
Trial Activity
20 trials
REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis
Recruiting·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 2/3·NCT06955416·312 enrolled
Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes
Recruiting·—·Phase 1/2·NCT07167693·60 enrolled
Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors
Not yet recruiting·—·Phase 2·NCT07421518·75 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)